Fintel reports that on October 6, 2025, Stifel maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy ...

Fintel reports that on October 6, 2025, Morgan Stanley maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds.

The company was one of many to get letters last month from the US Food and Drug Administration calling out what the agency ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Alnylam Pharmaceuticals, Inc. is one of them. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech ...

As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter ...

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 ...

The VanEck Biotech ETF (BBH) provides market-cap-weighted exposure to leading U.S.-listed biotechnology firms.

Our RNAi play came from the understanding that personalization and the development of curated therapies are the future of ...

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam ...

Alnylam Pharmaceuticals ( NASDAQ: ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart ...